These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26914029)

  • 1. A Clinical Evaluation of a Hepatitis C Nosode in the Treatment of Hepatitis C.
    Shah R
    J Altern Complement Med; 2016 Mar; 22(3):197-203. PubMed ID: 26914029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C Nosode: The preparation and homeopathic pathogenetic trial.
    Shah R
    Homeopathy; 2013 Jul; 102(3):207-14. PubMed ID: 23870381
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients.
    Reesink HW; Fanning GC; Farha KA; Weegink C; Van Vliet A; Van 't Klooster G; Lenz O; Aharchi F; Mariën K; Van Remoortere P; de Kock H; Broeckaert F; Meyvisch P; Van Beirendonck E; Simmen K; Verloes R
    Gastroenterology; 2010 Mar; 138(3):913-21. PubMed ID: 19852962
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE; Shire NJ; Cernohous P; Rouster SD; Omachi JH; Brun S; Da Silva B
    Clin Infect Dis; 2005 Oct; 41(8):1186-95. PubMed ID: 16163639
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive factors of virological non-response to interferon-ribavirin combination therapy for patients infected with hepatitis C virus of genotype 1b and high viral load.
    Akuta N; Suzuki F; Sezaki H; Suzuki Y; Hosaka T; Someya T; Kobayashi M; Saitoh S; Watahiki S; Sato J; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2006 Jan; 78(1):83-90. PubMed ID: 16299715
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low hepatitis C viral load predicts better long-term outcomes in patients undergoing resection of hepatocellular carcinoma irrespective of serologic eradication of hepatitis C virus.
    Shindoh J; Hasegawa K; Matsuyama Y; Inoue Y; Ishizawa T; Aoki T; Sakamoto Y; Sugawara Y; Makuuchi M; Kokudo N
    J Clin Oncol; 2013 Feb; 31(6):766-73. PubMed ID: 23129744
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response-guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: a pilot trial.
    Van den Eynde E; Crespo M; Esteban JI; Jardi R; Ribera E; Carbonell J; Rodríguez-Frias F; Falco V; Curran A; Imaz A; Villar del Saz S; Ocaña I; Esteban R; Pahissa A
    Clin Infect Dis; 2009 Apr; 48(8):1152-9. PubMed ID: 19275492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitation of hepatitis C virus RNA in peripheral blood mononuclear cells in HCV-monoinfection and HIV/HCV-coinfection.
    Chary A; Winters MA; Eisen R; Knight TH; Asmuth DM; Holodniy M
    J Med Virol; 2012 Mar; 84(3):431-7. PubMed ID: 22246828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation, standardization and in vitro safety testing of Mycobacterium nosodes (Emtact- polyvalent nosode).
    Joshi S; Mukerjee S; Vaidya S; Talele G; Chowdhary A; Shah R
    Homeopathy; 2016 Aug; 105(3):225-232. PubMed ID: 27473543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of acute hepatitis C in human immunodeficiency virus-infected patients: the HEPAIG study.
    Piroth L; Larsen C; Binquet C; Alric L; Auperin I; Chaix ML; Dominguez S; Duval X; Gervais A; Ghosn J; Delarocque-Astagneau E; Pol S;
    Hepatology; 2010 Dec; 52(6):1915-21. PubMed ID: 21064156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV Nosode: The Homeopathic Pathogenetic Trial.
    Shah R
    Forsch Komplementmed; 2015; 22(3):156-62. PubMed ID: 26335635
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of the efficacy of antiviral therapy for hepatitis C virus infection by an ultrasensitive RT-PCR assay.
    Kinai E; Hanabusa H; Kato S
    J Med Virol; 2007 Aug; 79(8):1113-9. PubMed ID: 17596840
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-treatment of patients with hepatitis C who failed to respond (nonresponders) to previous treatment.
    Sharvadze LG; Gogichaishvili ShSh; Sakandelidze TsG; Zhamutashvili MT; Chkhartishvili NI
    Georgian Med News; 2009 Jan; (166):61-4. PubMed ID: 19202222
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Amino acid substitutions in the hepatitis C virus core region of genotype 1b affect very early viral dynamics during treatment with telaprevir, peginterferon, and ribavirin.
    Akuta N; Suzuki F; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2010 Apr; 82(4):575-82. PubMed ID: 20166188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of early null response to pegylated interferon and ribavirin as a predictor of therapeutic nonresponse in patients undergoing treatment for chronic hepatitis C.
    Reau N; Satoskar R; Te H; DeVoss A; Elsen C; Reddy G; Mohanty S; Jensen D
    Am J Gastroenterol; 2011 Mar; 106(3):452-8. PubMed ID: 21063395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serial quantitation of serum core protein and viral RNA of hepatitis C virus after interferon therapy: increase in viral loads in biochemical responders.
    Yoshioka K; Aiyama T; Iwata K; Yano M; Okumura A; Ishikawa T; Kakumu S
    Am J Gastroenterol; 1997 Aug; 92(8):1305-9. PubMed ID: 9260795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load.
    Hofer H; Watkins-Riedel T; Janata O; Penner E; Holzmann H; Steindl-Munda P; Gangl A; Ferenci P
    Hepatology; 2003 Jan; 37(1):60-4. PubMed ID: 12500189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Shortened treatment duration in treatment-naive genotype 1 HCV patients with rapid virological response: a meta-analysis.
    Moreno C; Deltenre P; Pawlotsky JM; Henrion J; Adler M; Mathurin P
    J Hepatol; 2010 Jan; 52(1):25-31. PubMed ID: 19931204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early HCV RNA changes in patients with chronic hepatitis C treated with peginterferon alfa 2b and ribavirin.
    Gallegos-Orozco JF; Fuentes AP; Olivera-Martinez MA; Gutiérrez-Reyes G; Cortina D; Oregel JA; Pérez-Pruna C; Sixtos MS; Cruz-Castellanos S; Soto-Ramírez LE; Rodríguez-Díaz R; Fuentes-Romero L; Gutiérrez-Ruiz MC; Kershenobich D
    Rev Invest Clin; 2003; 55(2):138-42. PubMed ID: 12827916
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.